Callan Family Office LLC Grows Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Callan Family Office LLC increased its holdings in DexCom, Inc. by 141.4%, owning 7,389 shares valued at $505,000 after buying an additional 4,328 shares during the first quarter.
• Several analysts have raised their target prices for DexCom, with Raymond James increasing its target from $99.00 to $102.00, and Citigroup raising its target from $82.00 to $102.00 while maintaining a "buy" rating.
• DexCom reported $1.16 billion in revenue for the last quarter, a 15.2% increase year-over-year, and earnings per share of $0.48, surpassing analysts' expectations of $0.45.

Callan Family Office LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 141.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,389 shares of the medical device company's stock after buying an additional 4,328 shares during the quarter. Callan Family Office LLC's holdings in DexCom were worth $505,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of DXCM. Golden State Wealth Management LLC increased its position in DexCom by 211.2% during the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in shares of DexCom in the first quarter valued at approximately $27,000. Optiver Holding B.V. acquired a new position in shares of DexCom in the fourth quarter valued at approximately $33,000. Heck Capital Advisors LLC acquired a new position in shares of DexCom in the fourth quarter valued at approximately $38,000. Finally, Alpine Bank Wealth Management acquired a new position in shares of DexCom in the first quarter valued at approximately $40,000. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Trading Up 1.2%

DexCom stock traded up $0.99 during trading hours on Friday, reaching $80.95. 2,232,510 shares of the company's stock were exchanged, compared to its average volume of 3,826,104. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The firm's 50 day simple moving average is $83.05 and its 200 day simple moving average is $80.09. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The firm has a market capitalization of $31.74 billion, a PE ratio of 56.22, a PEG ratio of 1.68 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. During the same quarter last year, the firm earned $0.43 EPS. The firm's revenue for the quarter was up 15.2% compared to the same quarter last year. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on DXCM shares. Robert W. Baird decreased their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Raymond James Financial boosted their price target on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. Morgan Stanley boosted their price target on DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Piper Sandler boosted their price target on DexCom from $90.00 to $100.00 and gave the company an "overweight" rating in a research note on Thursday, July 31st. Finally, The Goldman Sachs Group began coverage on DexCom in a research note on Friday, May 30th. They issued a "buy" rating and a $104.00 price target for the company. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and an average target price of $99.89.

Insider Activity

In other DexCom news, EVP Michael Jon Brown sold 10,000 shares of DexCom stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the transaction, the executive vice president owned 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the transaction, the director directly owned 33,411 shares in the company, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,656 shares of company stock worth $2,412,191 in the last quarter. 0.32% of the stock is owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.